Trial · NCT07883382
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
NCT07883382, Phase 1, Phase 2, Recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation. Trials, record NCT07883382. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883382
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
- NCT number
- NCT07883382
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Myeloid Neoplasms With Myelofibrosis
- Interventions
- gecacitinib Hydrochloride Tablets
- First posted
- 2026-10-20
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Engraftment Rate at Day +28 Post-Transplant | Day +28 post-transplant | Percentage of patients who achieve both neutrophil engraftment (ANC \>0.5×10\^9/L for 3 consecutive days) and platelet engraftment (PLT \>20×10\^9/L for 7 consecutive days without platelet transfusion) by day +28 after transplantation. |
| Secondary | Incidence of Poor Graft Function (PGF) at Day +180 | Day +180 post-transplant | PGF is defined as persistent cytopenia(s), including ANC \<0.5×10\^9/L, PLT \<20×10\^9/L or platelet transfusion dependence, and/or Hb \<70 g/L or red blood cell transfusion dependence, lasting for at least 2 weeks after initial donor engraftment, with hypoplastic marrow, full donor chimerism, and exclusion of relapse, rejection, severe GVHD, active infection, drug-related myelosuppression, or other identifiable causes. |
| Secondary | Incidence of Grade III-IV Acute Graft-Versus-Host Disease (aGVHD) at Day +180 | Day +180 post-transplant | Percentage of patients developing grade III-IV acute GVHD within 180 days after transplantation, graded according to standard criteria. |
| Secondary | Overall Survival (OS) at 1 Year Post-Transplant | 1 year post-transplant | Overall survival is defined as the time from transplantation to death from any cause. The 1-year overall survival rate is the percentage of patients alive 1 year after transplantation. |
| Secondary | Incidence of Severe Infections Within 180 Days Post-Transplant | Within 180 days post-transplant | Percentage of patients experiencing grade ≥3 infections within 180 days after transplantation. |
| Secondary | Bone Marrow Fibrosis Grade Changes at Day +90 and Day +180 | Day +90 and Day +180 post-transplant | Proportion of patients with decreased, increased, or stable bone marrow fibrosis grade at day +90 and day +180 compared to baseline, assessed according to the 2016 WHO myelofibrosis grading criteria. |
| Secondary | Safety and Tolerability - Adverse Events | From start of study drug until 28 days after last dose | Incidence and severity of treatment-emergent adverse events (TEAEs), graded according to NCI-CTCAE v5.0 criteria. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883382
GET https://conductscience.org/api/trials/v1/NCT07883382/registered